FDA recommended potent drugs against COVID-19: Insight through molecular docking

Human Coronavirus (COVID-19) is a worldwide pandemic of 2019–20 that was emerged in China in December 2019. More than 37,000deaths with7, 84, 440confirmed cases has been reported from around 200 different countries has been reported till now and the number is increasing every second. The spread is said to be through human to human transmission via close contact or respiratory droplets produced when people cough or sneeze. No treatment for the illness has been approved yet. The urgent need is to find solution to this growing problem that has affected the whole mankind. World Health Organisation (WHO) as well as US Food and Drug Administration (FDA) are continuously working to find the solution. In the same line they have proposed many potent drugs that may have efficiency against the newly emerged viral infection. To support the efforts the present study is designed to carry out the in silico analysis viz. Docking studies of around 16drugs recently recommended by US FDA by observing the interaction of test molecules with SARS proteinase.